RHHBY - Regeneron's Skin Drugs Propel Revenue In Q3 Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug | Benzinga
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate.
Revenues increased 15% Y/Y to $3.36 billion, beating the consensus of $3.235 billion.
Dupixent global net sales (recorded by Sanofi) increased 33% to $3.10 billion versus the third quarter of 2022.
Third quarter 2023 U.S. net sales for Eylea (down 11%) and Eylea HD were $1.49 billion, including $43 million from Eylea HD (high dose version), primarily due to a lower net selling price driven ...